Central laboratory
FVIII levels and FVIII inhibitor titres are key parameters for assessing treatment outcomes in MOTIVATE
To investigate the impact of different treatment approaches on FVIII inhibitor titres and FVIII plasma levels, it is important that measurements are performed consistently for different patients. Performing the measurements at a single central laboratory may help to enable this.
Central laboratory
Participating centres have the opportunity to send samples to a central laboratory for FVIII and inhibitor measurements.
Central laboratory coordinators
Carmen Escuriola-Ettingshausen
Director, HZRM Hämophilie-Zentrum Rhein Main,
Mörfelden-Walldorf, Germany
Guy Young
Director, Hemostasis and Thrombosis Program, Children's Hospital Los Angeles,
Los Angeles, CA, US
